Abstract

The following review article presents clinical and experimental features of alcohol-induced liver disease (ALD). Basic aspects of alcohol metabolism leading to the development of liver hepatotoxicity are discussed. ALD includes fatty liver, acute alcoholic hepatitis with or without liver failure, alcoholic steatohepatitis (ASH) leading to fibrosis and cirrhosis, and hepatocellular cancer (HCC). ALD is fully attributable to alcohol consumption. However, only 10–20% of heavy drinkers (persons consuming more than 40 g of ethanol/day) develop clinical ALD. Moreover, there is a link between behaviour and environmental factors that determine the amount of alcohol misuse and their liver disease. The range of clinical presentation varies from reversible alcoholic hepatic steatosis to cirrhosis, hepatic failure, and hepatocellular carcinoma. We aimed to (1) describe the clinico-pathology of ALD, (2) examine the role of immune responses in the development of alcoholic hepatitis (ASH), (3) propose diagnostic markers of ASH, (4) analyze the experimental models of ALD, (5) study the role of alcohol in changing the microbiota, and (6) articulate how findings in the liver and/or intestine influence the brain (and/or vice versa) on ASH; (7) identify pathways in alcohol-induced organ damage and (8) to target new innovative experimental concepts modeling the experimental approaches. The present review includes evidence recognizing the key toxic role of alcohol in ALD severity. Cytochrome p450 CYP2E1 activation may change the severity of ASH. The microbiota is a key element in immune responses, being an inducer of proinflammatory T helper 17 cells and regulatory T cells in the intestine. Alcohol consumption changes the intestinal microbiota and influences liver steatosis and liver inflammation. Knowing how to exploit the microbiome to modulate the immune system might lead to a new form of personalized medicine in ALF and ASH.

Highlights

  • For the last 12 years, scientists from around the world have been participating in symposia dedicated to the scientific and clinical research of Charles S

  • Cytochrome p450 CYP2E1 activation may change the severity of alcoholic steatohepatitis (ASH)

  • We examined droplet dynamics in polarized hepatic cells treated with oleic acid (OA), a hepatotoxic fatty acid associated with the “Western” diet, in the presence or absence of ethanol

Read more

Summary

Introduction

For the last 12 years, scientists from around the world have been participating in symposia dedicated to the scientific and clinical research of Charles S. Cytochrome p450 (CYP) 2E1 activation may change the severity of ASH and NASH. Alcohol consumption changes the intestinal microbiota, and the toxic products of the microbiome (endotoxin) influence liver inflammation. We aimed to (1) describe the clinico-pathology of ALD, (2) examine the role of immune responses in the development of alcoholic hepatitis (ASH), (3) propose diagnostic markers of ASH, (4) analyze the experimental models of ALD, (5) study the role of alcohol in changing the microbiota, and (6). (7) identify pathways in alcohol-induced organ damage, and (8) target new innovative experimental concepts modeling the experimental approaches. The present review includes evidence recognizing the key toxic role of alcohol in ALD severity. Cytochrome p450 CYP2E1 activation may change the severity of ASH

Charles Lieber’s Scientific Legacy
Interleukin-8 Signaling Pathway in Alcoholic Hepatitis
FAT 10 in Alcoholic Hepatitis Pathogenesis
Other Findings
Graphs of FAT
The Role of Alcohol-Induced Microtubule Hyperacetylation in ASH Progression
Micro-RNA Profiling of Hepatic Macrophages in Alcoholic Liver Disease
Signature Pathway of Alcoholic Hepatitis—Integrative Global Analysis
Gut-Liver Challenge in Alcoholic Liver Disease
Liver Influences on Alcohol Drinking Behavior
10. Phenotyping Human CYP1A1 Polymorphisms Using Model Organisms
11. Alcohol and Non-Infectious Liver Diseases
12. Alcohol and Therapeutics Interaction
13. Conclusions
50 AMP-activated protein kinase
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call